Sessions in Detail

Sponsored Session: EBEWE - Treatment Strategies for Stroke & Neuroprotection
Chair: H. Sharma (SE)
10:15 - 12:15

10:15	Antisense transport across the BBB and treatment of Alzheimer's Disease	W. Banks (US)
10:35	Matrix metalloproteinases are modifiers of injury and recovery processes in the injured spinal cord	L. Noble (US)
10:55	The BBB: A gateway to neurological diseases	H. Sharma (SE)
11:15	TBC	N. Bornstein (IL)
11:35	TBC	D. Muresanu (RO)
11:55	New Experimental and therapeutic strategies for spinal cord and injury repair	E. Sykova (CZ)

Session 1: Neuronal regeneration
Chairs: G. Raivich (UK) & P. Salinas (UK)
15:00 - 17:20

15:00	Dual roles of the reticulon protein Nogo-A	Ch. Bandtlow (AT)
15:20	From neurite remodelling to synaptic assembly: a role for Wnt signalling.	P. Salinas (UK)
15:40	Novel strategies to promote peripheral axon regeneration	L. Klimaschewski (AT)
16:00	Intracellular signals and transcription factors in regeneration	G. Raivich (UK)
16:20	Targeting apoptosis and growth inhibition in the lesioned optic nerve	P. Lingor (DE)
16:40	Efficient preservation of motor function in an animal disease model of peripheral neuropathy in the presence of Neural Regeneration Peptides	F. Sieg (NL)
17:00	Neuroprotection by polyunsaturated fatty acid docosahexaenoic acid and calcium-independent phospholipases A2	G. Reiser (DE)

Session 2: Pathology of neurological diseases
Chair: A. Tolkovsky (UK)
17:40 - 19:40

17:40	Diabetic neuropathy: what is the problem?	A. Tolkovsky (UK)
18:00	Novel therapeutic strategies against ischemic injury	M. Schwaninger (DE)
18:20	Pathology of motoneuron diseases	T. Mennini (IT)
18:40	BDNF and synaptic consolidation: new insights and therapeutic implications	C. Bramham (NO)
19:00	Bid triggers caspase-independent cell death in neurons	C. Culmsee (DE)
19:20	Huntingtin and neuronal gene transcription in Huntington’s Disease	Ch. Zuccato (IT)
19:40	PPARg-agaonists - sweet strategy against neuroinflamation and neuronal death	T. Herdegen (DE)

Session 3: Analytical methods for basic and clinical research
Chair: R. Duden (UK)
08:30 - 09:50

08:30	Imaging membrane dynamics: visualization of trafficking pathways	R. Duden (UK)
08:50	Therapeutic strategies in Huntington's Disease: lessons from animal models	H.P. Nguyen (DE)
09:10	Inflammation in Parkinson’s disease: the role of activated microglia	H. Wilms (DE)
09:30	Endosomes and nervous system: Expression and function of mouse Stam2 gene	S. Gajovic (HA)

Session 4: Clinical research and therapeutic approaches I
Chair: H. Ehrenreich (DE)
10:10 - 11:30

10:10	Erythropoietin: A candidate compound for neuroprotection and neuroregeneration in human brain	H. Ehrenreich (DE)
10:30	Different ways to improve neuroprotection in Parkinson's disease	E. Hirsch (FR)
10:50	Hyperbaric oxygen as promising neuroprotective approach against stroke	C. Eschenfelder (DE)
11:10	New targets for pharmacological intervention in the glutamatergic synapse	F. Gardoni (IT)

Sponsored Session: Merck Serono- Vitamin B Deficiency in Neurological Diseases
Chair: M. Zimmermann
11:30 - 13:00

11:30	B vitamins efficacy and TNFα in a rat model of diabetic neuropathy	C. Jolivalt (US)
11:55	New horizons for vitamin B12 (colalamin) in neurobiology	G. Scalabrino (IT)
12:20	Analgesic and neuroprotective potentials of B-vitamins?	M. Zimmermann (DE)
12:55	Discussion	ALL

Sponsored Session: Xigen - Peptides as Therapeutic Strategy
Chair: Ch. Bonny (CH)
17:00 - 19:00

17:00	JNK signalling pathway following MCAo: neuroportective effext of JNK inhibitor peptide (D-JNKI-1)	T. Borsello (IT)
17:25	D-JNKI-1-medicated neuroprotection and induced endocytosis in cerebral ischenia	J. Puyal (CH)
17:50	Implications of ATP-binding Cassette transporters for brain pharmacotherapies	D. Hermann (CH)
18:15	First-in-man phase I on selected stroke patients and phase II clinical program with D-JNKI-1 (XG-102-533-phase I/II)	M. Reichhart (CH)
18:40	Discussion	ALL

Session 5: Part 1: Blood Brain Barrier, Neuroprotection and Neurotoxicity
Chairs: H. Sharma (SE) & TBC
09:00 - 10:30

09:00	Keynote Lecture: Protective approaches against anesthetic-induced neurodegeneration during development.	W. Slikker (US)
09:30	Choroid plexus vs. blood-brain barrier: their roles in staving off the brain ß-amyloid retention in aging, NPH and Alzheimer's Disease	C. Johanson (US)
09:50	Brain hyperthermia in drugs of abuses	E. Kiyatkin (US)
10:10	Are glio-vascular and glio-neuronal interactions determinants for axonal regeneration?	H. Wolburg (DE)

Session 5: Part 2: Blood Brain Barrier, Neuroprotection and Neurotoxicity
Chairs: H. Sharma (SE) & TBC
10:40 - 12:00

10:40	Transglutaminases: cross-linking a-synuclein to the pathogenesis of Parkinson's disease	B. Drukarch (NL)
11:00	Nitric oxide mediated cGMP-positive structures in the rat brain: colocalisation with cholinergic or serotonergic systems and involvement with depression and cognition	H. Steinbusch (NL)
11:20	BBB in neuroprotection and nuroregeneration	H. Sharma (SE)
11:40	Multiple sclerosis and blood-brain barrier function	J. Kirk (IE)

Session 6: Clinical research and therapeutic approaches: II. Clinical Studies
Chair: D. Muresanu (RO)
13:00 - 15:00

13:00	Neuroprotection in multiple sclerosis	O. Bajenaru (RO)
13:20	Treatment options for traumatic diffuse axonal injury	P. Vos (NL)
13:40	Neuroinflammation and atherosclerosis	N. Bornstein (IL)
14:00	Prophylaxis in neuroprotection. An innovative approach.	L. Csiba (HU)
14:20	Kynurenines in the brain: neurodegeneration and neuroprotection	L. Vecsei (HU)
14:40	Clinical Neuroprotection - how close are we to making a dream come true?	D. Muresanu (RO)